CLEC9A Protein, Human, Recombinant (hFc)

Catalog No. TMPK-01057

CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.

CLEC9A Protein, Human, Recombinant (hFc)

Catalog No. TMPK-01057

Pack Size	Price	Availability
100 μg	397 €	7-10 days
500 μg	1.586 €	7-10 days
1 mg	2.660 €	7-10 days

Bulk & Custom

Add to Cart

Questions

Resource Download

User Guide of Recombinant Proteins

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Information

Biological Activity	Immobilized Human CLEC9A, hFc Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Anti-CLEC9A Antibody, hFc Tag with the EC50 of 4.4ng/ml determined by ELISA.
Description	CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.
Species	Human
Expression System	HEK293 Cells
Tag	N-hFc
Accession Number	Q6UXN8
Synonyms	UNQ9341,HEEE9341,DNGR-1,CLEC9A,CD370,9830005G06Rik
Construction	Lys57-Val241
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	48.5 kDa (predicted). Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.
Endotoxin	< 1 EU/μg by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.